Published in J Clin Gastroenterol on January 01, 2014
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol (2016) 0.78
Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. World J Gastroenterol (2015) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology (2007) 4.58
An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol (2009) 3.99
A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med (2008) 3.91
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther (2007) 2.79
An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol (2001) 2.30
Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol (2011) 2.19
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut (2008) 2.16
Two randomized trials of linaclotide for chronic constipation. N Engl J Med (2011) 2.14
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther (2007) 2.08
Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging (2010) 2.08
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther (2008) 2.06
Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil (2012) 2.03
Systematic review on the management of chronic constipation in North America. Am J Gastroenterol (2005) 1.85
Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther (2010) 1.80
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther (2012) 1.79
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol (2010) 1.74
Efficacy of linaclotide for patients with chronic constipation. Gastroenterology (2010) 1.71
Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut (1999) 1.67
Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci (2013) 1.61
5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil (2008) 1.59
Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil (2009) 1.58
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol (2007) 1.57
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther (2010) 1.56
The treatment of chronic constipation in adults. A systematic review. J Gen Intern Med (1997) 1.49
A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther (2008) 1.49
Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol (2005) 1.44
Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci (2011) 1.35
Adverse effects of laxatives. Dis Colon Rectum (2001) 1.28
A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil (2010) 1.27
Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil (2009) 1.27
Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol (2004) 1.27
Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol (2009) 1.26
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol (2001) 1.23
Chronic constipation: an evidence-based review. J Am Board Fam Med (2011) 1.23
Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci (2009) 1.19
Long-term results of biofeedback treatment for faecal incontinence: a comparative study with untreated controls. Colorectal Dis (2009) 1.18
Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther (2010) 1.16
Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J Cardiovasc Pharmacol Ther (2010) 1.14
Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil (2009) 1.14
Optimal treatment of chronic constipation in managed care: review and roundtable discussion. J Manag Care Pharm (2008) 1.13
Epidemiology and burden of chronic constipation. Can J Gastroenterol (2011) 1.13
Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil (2001) 1.11
Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci (2011) 1.06
Chronic constipation: current treatment options. Can J Gastroenterol (2011) 1.05
Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci (2002) 1.02
Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther (1995) 0.97
Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol (2012) 0.96
Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol (1999) 0.95
Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother (2009) 0.94
Frequency of functional bowel disorders among healthy volunteers in Mexico City. Dig Dis (2006) 0.93
The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. Gastroenterol Res Pract (2012) 0.92
Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil (2011) 0.91
Drugs and constipation in elderly in nursing homes: what is the relation? Gastroenterol Res Pract (2012) 0.88
Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders. Expert Opin Drug Metab Toxicol (2008) 0.84
[Guidelines for diagnosis and treatment of constipation in Mexico. A) Epidemiology (meta-analysis of the prevalence), pathophysiology and classification]. Rev Gastroenterol Mex (2011) 0.78
Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits? Naunyn Schmiedebergs Arch Pharmacol (2011) 0.77
[What people mean by constipation? A general population based-study.]. Rev Gastroenterol Mex (2010) 0.76
[The Latin-American Consensus on Chronic Constipation]. Gastroenterol Hepatol (2008) 0.76
Laxatives for chronic constipation in adults. BMJ (2012) 0.76
HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol (2010) 0.95
Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One (2012) 0.93
Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes. Ann Hepatol (2012) 0.78
Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab. J Crohns Colitis (2011) 0.76
Hepatotoxicity from ingestion of wild mushrooms of the genus Amanita section Phalloideae collected in Mexico City: two case reports. Ann Hepatol (2011) 0.75